Do inotropes improve 30-day mortality in patients with cardiogenic shock?
In a large national registry of patients with cardiogenic shock, the use of inotropes was associated with significantly higher 30-day mortality, highlighting the need for cautious use and further randomized trials.
BACKGROUND: The use of inotropic agents in treating cardiogenic shock (CS) remains controversial. This study investigates the effect of inotropes on 30-day mortality in CS patients using data from the SWEDEHEART registry (The Swedish Web-system for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapies). METHODS AND RESULTS: Data were sourced from the national SWEDEHEART registry for all CS patients in Sweden from 2000 to 2022. The primary endpoint was 30-day all-cause mortality. We employed multilevel Cox proportional-hazards regression with instrumental variable and inverse probability weighting propensity score to adjust for confounders. The treatment-preference instrument was the quintile of preference for inotrope use at the treating hospital. A total of 16 214 patients (60.5% men, 39.5% women) were included; 23.5% had diabetes, 10.2% had a previous myocardial infarction (MI), and 13.8% had previous heart failure (HF). The median age was 70 years interquartile range (IQR); 19, with 66.4% over 70. Acute coronary syndrome (ACS) caused CS in 82.9%. Inotropes were administered to 43.8% of patients, while 56.2% did not receive them. There were 7875 (48.1%) deaths. Patients treated with inotropes were, on average, 2 years younger and more likely to have ACS, while those not treated had more previous MI and were less likely to undergo percutaneous coronary intervention (PCI). The number of CS cases decreased by 12% per year (Ptrend < 0.001), and inotrope use increased by 5% per year (Ptrend < 0.001). Unadjusted mortality in CS rose by 2% per calendar year (Ptrend < 0.001). Inotropes were associated with higher mortality adjusted hazard ratio (HR) 1.72; 95% CI 1.26-2.35; P = 0.001, with significant interactions between inotrope treatment, age, and diagnosis (Pinteraction < 0.001 and Pinteraction = 0.018). CONCLUSION: In this observational study, inotropes were linked to higher mortality in CS patients, particularly those younger than 70. While CS cases decreased, inotrope use and mortality increased in Sweden.
Pétursson et al. (Tue,) studied this question.